Phase III Trial of Osimertinib and Bevacizumab in EGFR-Mutant Lung Cancer
A phase III trial is comparing osimertinib alone versus its combination with bevacizumab in patients with EGFR-mutant non-small cell lung cancer.
Asset / Drug
Drug and asset intelligence for Osimertinib with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.